

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	LUBISCH	Art Unit	1625
Serial No.:	10/574,211	Examiner:	Chandrakumar, Nizal S.
Filed:	January 22, 2007	Conf. No.	5690
For:	Heteroaryl-Substituted 1,3-Dihydroindol-2-One Derivatives and Medicaments Containing Them		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, Applicants submit the attached PTO/SB/08A form for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

Applicants believe the enclosed Information Disclosure Statement is entitled to the benefit of 37 CFR §1.97 (b) (4) as it is being filed before the mailing of the first Office Action after the filing of a Request for Continued Examination under § 1.114. Accordingly, Applicants believe that no fee or certification is required.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 50-1662.

Respectfully submitted,

POLSINELLI SHUGHART PC

Date: August 13, 2010

/Andrea M. Porterfield/

Andrea M. Porterfield, Registration No.: 55,311
700 W. 47th Street, Suite 1000
Kansas City, MO 64112
Phone: (816) 360-4119
Email: aporterfield@polsinelli.com
Attorneys for Applicant